Effectiveness of Mepolizumab in Reducing Asthma Exacerbations in Japan
H. Nagase (Tokyo, Japan), J. Tamaoki (Tokyo, Japan), T. Suzuki (Tokyo, Japan), Y. Nezu (Tokyo, Japan), A. Cole (Collegeville, United States of America), S. Yang (Collegeville, United States of America), G. Mu (Collegeville, United States of America), M. Katsumata (Tokyo, Japan), M. Komatsubara (Tokyo, Japan), R. Alfonso (Collegeville, United States of America)
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Session: Monoclonal antibodies in asthma
Session type: E-poster session
Number: 2219
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Nagase (Tokyo, Japan), J. Tamaoki (Tokyo, Japan), T. Suzuki (Tokyo, Japan), Y. Nezu (Tokyo, Japan), A. Cole (Collegeville, United States of America), S. Yang (Collegeville, United States of America), G. Mu (Collegeville, United States of America), M. Katsumata (Tokyo, Japan), M. Komatsubara (Tokyo, Japan), R. Alfonso (Collegeville, United States of America). Effectiveness of Mepolizumab in Reducing Asthma Exacerbations in Japan. 2219
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: